ERBB2 and neoplasm: Since T cell engagers (TCEs) are perhaps the most therapeuticallyrelevant class of bsAbs, we chose to attempt the grafting of a FabHER2 and a FabCD3 on FcCD20, with theaim to produce an “IgG-like TCE”, able to recruit Tcells (through CD3-binding) to HER2+ tumor cells.